Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients

By LabMedica International staff writers
Posted on 23 Jun 2025

Critically ill patients in medical intensive care units (MICUs) often suffer from conditions such as acute respiratory distress syndrome (ARDS) or sepsis, which are linked to reduced diversity of gut microbiota and altered concentrations of microbiome-related metabolites. More...

These metabolites have been associated with patient survival and could represent modifiable factors to improve outcomes. Now, researchers have developed a novel diagnostic tool—a metabolic dysbiosis score (MDS)—based on fecal metabolite profiling that can identify critically ill patients at higher risk of 30-day mortality.

The study, conducted by researchers at the University of Chicago (Chicago, IL, USA), aimed to uncover gut microbiome characteristics and metabolic signatures associated with mortality in patients admitted to the MICU for non–COVID–19 respiratory failure or shock. To develop the tool, the researchers performed a prospective observational cohort study involving 196 critically ill patients. Fecal specimens were collected shortly after ICU admission and analyzed using shotgun metagenomic sequencing to define microbiome composition, along with mass spectrometry to quantify microbiota-derived metabolites. The findings, published in Science Advances, show that individual metabolite levels and microbial compositions in the initial samples did not correlate directly with 30-day mortality

However, a specific combination of metabolite concentrations led to the creation of the MDS from fecal concentrations of 13 specific metabolites found in the first fecal sample after ICU admission. It showed a statistically significant independent association with 30-day mortality, offering a metabolic snapshot that could help clinicians identify patients at greater risk of poor outcomes. Importantly, this approach highlights the functional activity of the microbiome, beyond just taxonomic profiling. The MDS offers a new, non-invasive method to stratify critically ill patients based on their likelihood of survival. It opens the door for targeted interventions, such as microbiome-augmentation strategies, by identifying patients who might benefit most. The researchers suggest that fecal metabolic profiling could guide future clinical trials focused on improving outcomes through modulation of the gut microbiota.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.